- Home
- XPON vs BIAF Comparison
XPON vs BIAF Comparison
Compare XPON & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPON
- BIAF
- Stock Information
- Founded
- XPON 2016
- BIAF 2014
- Country
- XPON United States
- BIAF United States
- Employees
- XPON N/A
- BIAF N/A
- Industry
- XPON Electronic Components
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- XPON Technology
- BIAF Health Care
- Exchange
- XPON Nasdaq
- BIAF Nasdaq
- Market Cap
- XPON 6.2M
- BIAF 6.7M
- IPO Year
- XPON 2022
- BIAF 2022
- Fundamental
- Price
- XPON $1.21
- BIAF $1.92
- Analyst Decision
- XPON
- BIAF Hold
- Analyst Count
- XPON 0
- BIAF 1
- Target Price
- XPON N/A
- BIAF N/A
- AVG Volume (30 Days)
- XPON 2.0M
- BIAF 186.7K
- Earning Date
- XPON 11-13-2025
- BIAF 11-14-2025
- Dividend Yield
- XPON N/A
- BIAF N/A
- EPS Growth
- XPON N/A
- BIAF N/A
- EPS
- XPON N/A
- BIAF N/A
- Revenue
- XPON $9,417,947.00
- BIAF $6,776,739.00
- Revenue This Year
- XPON $61.26
- BIAF N/A
- Revenue Next Year
- XPON N/A
- BIAF $20.04
- P/E Ratio
- XPON N/A
- BIAF N/A
- Revenue Growth
- XPON 109.37
- BIAF N/A
- 52 Week Low
- XPON $0.60
- BIAF $1.76
- 52 Week High
- XPON $5.50
- BIAF $46.53
- Technical
- Relative Strength Index (RSI)
- XPON 40.65
- BIAF 39.11
- Support Level
- XPON $1.11
- BIAF $1.91
- Resistance Level
- XPON $1.32
- BIAF $2.25
- Average True Range (ATR)
- XPON 0.11
- BIAF 0.19
- MACD
- XPON -0.00
- BIAF -0.04
- Stochastic Oscillator
- XPON 18.32
- BIAF 10.42
About XPON Expion360 Inc.
Expion360 Inc is focused on the design, assembly, manufacturing, and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles (RV's) and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.